Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
$10M milestone payment from Merck triggeredAgenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus...
-
AGEN1181: New clinical responses and intratumoral Treg depletionAGEN1777 (TIGIT) is Fc enhanced for optimized immune performance & broader benefitAGEN2373 (anti-CD137): Clinical benefit with no...
-
LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
-
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass.,...
-
Balstilimab rolling BLA filing and FDA review underwayCOVID-19 trial open with patients in screening for iNKT Cell TherapyNew data and clinical responses with AGEN1181 to be presented at SITC on NOV11...
-
LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
-
Clinical Responses: AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimabClinical Data: Zalifrelimab efficacy in refractory rare tumorsClinical & Preclinical Data: AGEN 2373 (anti-CD137)Phase 2 Data:...
-
LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
-
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
-
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4)...